Richard Barker
Professor Richard W Barker is an internationally respected leader in healthcare and life sciences. He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the development and adoption of precision medicine. He also founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK academic initiative aimed at bringing biomedical advances more rapidly and affordably to patients. He is chairman of the South London Health Innovation Network and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the …
Professor Richard W Barker is an internationally respected leader in healthcare and life sciences.
He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the development and adoption of precision medicine. He also founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK academic initiative aimed at bringing biomedical advances more rapidly and affordably to patients.
He is chairman of the South London Health Innovation Network and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the impact of therapy on disease and is a board member of Celgene, a major US-based bio-therapeutics company.
His 30-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. The senior roles he has held include: Director General of the Association of the British Pharmaceutical Industry, General Manager of Healthcare Solutions for IBM, Chief Executive of Chiron Diagnostics and head of McKinsey’s European healthcare practice.
His book on the future of healthcare ‘2030 - The Future of Medicine: Avoiding a Medical Meltdown’ and his second book ‘Bioscience – lost in translation?’ are published by Oxford University Press.
He was awarded an OBE in the 2012 Honours List for services to the pharmaceutical industry.
He also holds a Visiting Professorship at Oxford University and an honorary chair at UCL, and is an honorary fellow of the British Pharmacological Society.
See more
He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the development and adoption of precision medicine. He also founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK academic initiative aimed at bringing biomedical advances more rapidly and affordably to patients.
He is chairman of the South London Health Innovation Network and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the impact of therapy on disease and is a board member of Celgene, a major US-based bio-therapeutics company.
His 30-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. The senior roles he has held include: Director General of the Association of the British Pharmaceutical Industry, General Manager of Healthcare Solutions for IBM, Chief Executive of Chiron Diagnostics and head of McKinsey’s European healthcare practice.
His book on the future of healthcare ‘2030 - The Future of Medicine: Avoiding a Medical Meltdown’ and his second book ‘Bioscience – lost in translation?’ are published by Oxford University Press.
He was awarded an OBE in the 2012 Honours List for services to the pharmaceutical industry.
He also holds a Visiting Professorship at Oxford University and an honorary chair at UCL, and is an honorary fellow of the British Pharmacological Society.
Articles: Richard Barker
China: A New Biopharma Model Emerging
China / Professor Richard Barker, founder of New Medicine Partners reflects on China’s very different approach to the biopharma industry. Napoleon once said: “China is a sleeping giant. Let her sleep, for when she wakes she will shake the world.” Well, in biotech, she is now wide awake I’ve recently returned from a four-day biotech conference in…
One Business or Two? The Era of Precision Medicine
R&D / In my career, I’ve held senior roles in both the biopharma and diagnostics sectors. Working across different cost structures, different business issues, and different regulatory systems in different parts of the world. I was once challenged as a new CEO in diagnostics by a pharma analyst to explain why I would want to join a…
